U.S. patent application number 10/304862 was filed with the patent office on 2003-07-03 for composition containing at least one oxidation-sensitive hydrophilic active principle and at least one n-vinylimidazole polymer or copolymer useful to prevent and/or treat cutaneous signs of intrinsic ageing.
This patent application is currently assigned to L'OREAL. Invention is credited to Biatry, Bruno, Lheureux, Eric.
Application Number | 20030125378 10/304862 |
Document ID | / |
Family ID | 8869872 |
Filed Date | 2003-07-03 |
United States Patent
Application |
20030125378 |
Kind Code |
A1 |
Biatry, Bruno ; et
al. |
July 3, 2003 |
Composition containing at least one oxidation-sensitive hydrophilic
active principle and at least one N-vinylimidazole polymer or
copolymer useful to prevent and/or treat cutaneous signs of
intrinsic ageing
Abstract
The invention relates to a composition containing, preferably in
a physiologically acceptable medium comprising an aqueous phase, at
least one oxidation-sensitive hydrophilic active principle selected
from the group consisting of ascorbic acid and its derivatives and
at least one non-crosslinked N-vinylimidazole polymer or copolymer,
the active principle and the polymer or copolymer both being in the
aqueous phase, useful for preventing and/or treating cutaneous
signs of intrinsic ageing.
Inventors: |
Biatry, Bruno; (Vincennes,
FR) ; Lheureux, Eric; (Montgeron, FR) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
L'OREAL
Paris
FR
|
Family ID: |
8869872 |
Appl. No.: |
10/304862 |
Filed: |
November 27, 2002 |
Current U.S.
Class: |
514/458 ;
424/486; 514/460; 514/474 |
Current CPC
Class: |
A61Q 19/02 20130101;
A61Q 5/08 20130101; A61P 17/00 20180101; A61P 43/00 20180101; A61K
2800/522 20130101; A61P 17/16 20180101; A61Q 19/08 20130101; A61K
8/676 20130101; A61K 8/817 20130101 |
Class at
Publication: |
514/458 ;
424/486; 514/460; 514/474 |
International
Class: |
A61K 031/355; A61K
031/35; A61K 031/375; A61K 009/14 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 28, 2001 |
FR |
0445375 |
Nov 28, 2001 |
FR |
0115375 |
Claims
1. A method for preventing and/or treating cutaneous signs of
intrinsic ageing, comprising applying a composition comprising a
physiologically acceptable medium comprising an aqueous phase, at
least one oxidation-sensitive hydrophilic active principle selected
from the group consisting of ascorbic acid and its derivatives, and
at least one non-crosslinked N-vinylimidazole polymer or copolymer
to a cutaneous tissue, the at least one active principle and the at
least one polymer or copolymer both being present in the aqueous
phase of the composition.
2. The method according to claim 1, wherein said derivatives of
ascorbic acid are selected from the group consisting of esters and
salts of ascorbic acid.
3. The method according to claim 1, wherein said composition
comprises a derivative of ascorbic acid selected from the group
consisting of esters and salts of ascorbic acid.
4. The method according to claim 3, wherein the hydrophilic active
principle is selected from the group consisting of
5,6-di-O-dimethylsilylascorbate, dl-.alpha.-tocopheryl dl-ascorbyl
phosphate potassium salt, magnesium ascorbyl phosphate and sodium
ascorbyl phosphate.
5. The method according to claim 1, wherein the oxidation-sensitive
hydrophilic active principle is ascorbic acid.
6. The method according to claim 1, wherein the composition
comprises a non-crosslinked copolymer that is a combination of the
N-vinylimidazole with N-vinylpyrrolidone and/or N-vinylcaprolactam
subunits.
7. The method according to claim 1, wherein the composition
comprises a non-crosslinked copolymer that is an
N-vinylimidazole/N-vinylpyrrolidone copolymer.
8. The method according to claim 1, wherein the composition
comprises a non-crosslinked copolymer selected from the group
consisting of a vinylpyrrolidone/vinylimidazole (50/50) copolymer
having a weight-average molar mass of 1 200 000 and a
vinylpyrrolidone/vinylimidazole (50/50) copolymer having a
weight-average molar mass of 10 000.
9. The method according to claim 1, wherein a molar ratio of
N-vinylimidazole unit equivalent to the oxidation-sensitive
hydrophilic active principle is from 0.004 to 16.
10. The method according to claim 9, wherein the molar ratio of the
N-vinylimidazole unit equivalent to the oxidation-sensitive
hydrophilic active principle is from 0.01 to 1.
11. The method according to claim 1, wherein the polymer or
copolymer is present at a concentration of 0.1 to 5% by weight of
the aqueous phase.
12. The method according to claim 11, wherein the polymer or
copolymer is present at a concentration of 0.1 to 2% by weight of
the aqueous phase.
13. The method according to claim 1, wherein the polymer or
copolymer has a molar fraction of N-vinylimidazole units of between
0.1 and 1.
14. The method according to claim 13, wherein the polymer or
copolymer has a molar fraction of N-vinylimidazole units of between
0.4 and 0.9.
15. The method according to claim 1, wherein the composition
further comprises an agent different from said hydrophilic active
principle which stimulates dermal macromolecules or which prevents
their decomposition and/or an agent different from said hydrophilic
active principle which stimulates the proliferation of fibroblasts
or keratinocytes and/or the differentiation of keratinocytes.
16. The method according to claim 1, wherein said cutaneous tissue
is selected from the group consisting of skin and mucous membranes.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to a composition comprising at
least one oxidation-sensitive hydrophilic active principle and at
least one N-vinylimidazole polymer or copolymer in a
physiologically acceptable medium comprising an aqueous phase, and
its use in particular to prevent or treat cutaneous signs of
intrinsic ageing. The composition is preferably a cosmetic or
dermatological composition.
BACKGROUND OF THE INVENTION
[0002] It is known to introduce, into cosmetic compositions,
various active principles intended to contribute specific
treatments to the skin and/or hair. However, some of these active
principles exhibit the disadvantage of being unstable in an aqueous
medium and of easily decomposing on contact with water, in
particular because of oxidation phenomena. They thus rapidly lose
their activity over time and this instability conflicts with the
desired effectiveness.
[0003] Attempts have thus been made for a long time to formulate
ascorbic acid or vitamin C because of its numerous beneficial
properties. In particular, ascorbic acid stimulates the synthesis
of the connective tissue and in particular of collagen, strengthens
the defences of the cutaneous tissue against external attacks, such
as ultraviolet radiation and pollution, compensates for vitamin E
deficiency of the skin, depigments the skin and has a role in
combating free radicals. These last two properties make it an
excellent candidate as cosmetic or dermatological active principle
for combating ageing of the skin or for preventing ageing of the
skin. Unfortunately, because of its chemical structure (of
.alpha.-ketolactone), ascorbic acid is highly sensitive to certain
environmental parameters and in particular to oxidation phenomena.
There thus ensues rapid decomposition of formulated ascorbic acid
in the presence of these parameters and in particular in the
presence of oxygen, light or metal ions, as a function of the
temperature or under certain pH conditions (Pharm. Acta. Helv.,
1969, 44, 611-667; STP Pharma, 1985, 4, 281-286).
[0004] Several solutions have thus been envisaged in the prior art
for reducing and/or slowing down the decomposition of ascorbic
acid.
[0005] Provision has thus been made to use ascorbic acid in the
form of a chemical derivative (magnesium ascorbyl phosphate or
esters of fatty acids and ascorbic acid), but the bioavailability
of these derivatives is very low (J. Am. Acad. Dermatol., 1996, 34,
29-33).
[0006] The instability of ascorbic acid with respect to oxygen can
be improved by using specific packagings, such as twin compartments
under an inert atmosphere, as disclosed in U.S. Pat. No. 5,935,584,
or alternatively by the use of two-phase emulsions, one phase of
which is composed of a dry powder comprising ascorbic acid and the
second phase of which is a liquid phase. The mixing of the two
phases has to be carried out at the time of use (WO 98/43598).
These solutions have disadvantages with regard to the cost and the
complexity of the manufacturing operations and significant
restrictions with regard to use.
[0007] Another solution provided in the prior art consists in using
a high concentration of glycols or polyols in order to reduce the
solubility of oxygen in the formulation, thus protecting the
ascorbic acid (WO 96/24325, EP 0 755 674, U.S. Pat. No. 5,981,578).
The polyols can optionally be incorporated in liposomes, as
disclosed in U.S. Pat. No. 6,020,367. However, these solutions
exhibit the disadvantage of resulting in sticky formulations, the
cosmetic quality of which is difficult to improve. Furthermore, the
presence of a high concentration of these compounds can lead to
phenomena of irritation.
[0008] Ascorbic acid can also be formulated in anhydrous media,
such as silicones (U.S. Pat. No. 6,194,452), which are capable of
creating an anhydrous barrier around ascorbic acid. A major
disadvantage of such solutions results from the lack of freshness
on application.
[0009] The need thus remains for a composition employable in
particular in the cosmetics field, in which a hydrophilic active
principle which is unstable in an oxidizing medium is stabilized,
which is comfortable on application, which does not lead to any
skin irritation after application and which is compatible with the
constraints of an industrial implementation of its manufacturing
process.
[0010] The effect of ascorbic acid on the biosynthesis of collagen,
a protein macromolecule predominantly present in the dermis, has
been known for several years (Arch. Biochem. Biophys., 152, 1972,
p. 318-328). It acts at two levels. First of all, as cofactor of
hydroxylases, enzymes involved in the hydroxylation of proline and
of lysine, ascorbic acid promotes this essential stage in the
assembling of procollagen molecules (Biochemistry, 78(5), 1981, p.
2279-2282; The Yale Journal of Biology and Medecine, 58, 1985, p.
553-559). Furthermore, it stimulates the biosynthesis of collagen
by increasing the amount of mRNA coding for procollagens of type I
and III (The Journal of Investive Dermatology, 90(4), 1988, p.
420-424).
[0011] Magnesium ascorbyl phosphate also stimulates the synthesis
of collagen (Skin Pharmacol., 6, 1993, p. 65-71).
[0012] At the same time as these properties, the ascorbic acid used
to treat cutaneous fibroblasts has made it possible to demonstrate
an increase in proteoglycans (Journal of Biochemical Engineering,
1991, 113).
[0013] More recently, it has been shown that magnesium ascorbyl
phosphate, added to a medium for the culturing of reconstructed
skin, led to a significant increase in the number of fibroblasts in
the lattice, in combination with significant stimulation of the
synthesis of proteins of the extracellular matrix (FR-02/01510).
This was observed in particular at the dermoepidermal junction,
where stimulation of the synthesis of the major components, which
are collagens IV and VII, and laminin, is measured. This phenomenon
has the consequence of reinforcing the relief of this junction,
promoting exchanges between dermis and epidermis, and the cohesion
of these two tissues, and thus makes it possible to combat the
harmful effects of ageing on these factors.
[0014] By enhancing the overall content of collagen, the
proliferative capability and the synthetic activity of fibroblasts
and the amount of procollagen I and III, but also by reinforcing
the cohesion and the effectiveness of the dermoepidermal junction,
ascorbic acid and its derivatives are therefore particularly useful
in preventing and/or treating cutaneous signs of intrinsic
ageing.
OBJECTS OF THE INVENTION
[0015] One object of the present invention is to provide a
composition comprising an oxidation-sensitive active principle for
example selected from the group consisting of ascorbic acid and its
derivatives, which exhibits good cosmetic properties, both with
regard to touch and with regard to tolerance, the preservation of
which over time does not require specific precautions, and which
retains the activity of the said active principle in the prevention
and/or the treatment of cutaneous signs of intrinsic ageing.
DETAILED DESCRIPTION OF THE INVENTION
[0016] The inventors have discovered that the use of
non-crosslinked N-vinylimidazole polymers or copolymers in
compositions in which the aqueous phase includes an
oxidation-sensitive active principle, such as ascorbic acid or one
of its derivatives, makes it possible to achieve the abovementioned
aim.
[0017] In the prior art, some compounds having an imidazole
structure have been disclosed for their stabilizing properties.
Thus, in Patent Application EP 0 586 106, several imidazole-based
molecules are used to stabilize certain retinoids against chemical
decomposition. Furthermore, polymeric emulsifiers composed of
N-vinylimidazole, of alkyl acrylates and of vinyl acetates are
disclosed in U.S. Pat. No. 4,057,622. They are used for the purpose
of replacing known emulsifiers in order to overcome their
disadvantages, in particular with regard to smell, and to stabilize
water-in-oil emulsions. Finally,
N-vinylimidazole/N-vinylcaprolactam/N-vi- nylpyrrolidone copolymers
are disclosed in U.S. Pat. No. 6,191,188. They are used in the
manufacture of hair-strengthening compositions.
[0018] To the knowledge of the inventors, polymers or copolymers
comprising N-vinylimidazole units have never been used in
combination with hydrophilic active principles sensitive to
decomposition by oxidation for the purpose of improving their
stability in an aqueous medium. This is true in particular in the
case of ascorbic acid.
[0019] One embodiment of the present invention is therefore the
preferably cosmetic and/or dermatological use, for preventing
and/or treating cutaneous signs of intrinsic ageing, of a
composition comprising, in a physiologically acceptable medium
comprising an aqueous phase, at least one oxidation-sensitive
hydrophilic active principle preferably selected from the group
consisting of ascorbic acid and its derivatives and at least one
non-crosslinked N-vinylimidazole polymer or copolymer, the active
principle and the polymer or copolymer both being in the aqueous
phase. The copolymer is preferably present in an amount sufficient
to stabilize the said oxidation-sensitive hydrophilic active
principle, and the composition is preferably applied to those areas
of the skin in need of such prevention and/or treatment.
[0020] Another embodiment of the invention is the use of a
combination composed of at least one oxidation-sensitive
hydrophilic active principle preferably selected from the group
consisting of ascorbic acid and its derivatives and of at least one
non-crosslinked N-vinylimidazole polymer or copolymer in the
aqueous phase-of a cosmetic composition as agent for preventing
and/or treating cutaneous signs of intrinsic ageing.
[0021] According to the invention, the term "intrinsic ageing" is
understood to mean the ageing which occurs because of modifications
due to endogenous factors, in contrast to ageing caused by
exogenous factors, such as photoageing. The changes in the skin
which occur are then revealed for example by a thinning of the
dermis, a loss of elasticity, a deepening of the imperfections and
the appearance of fine lines.
[0022] According to the invention, the term "hydrophilic active
principle" is understood to mean a compound having a solubility in
water of at least 0.25% at ambient temperature (25.degree. C.).
[0023] According to the invention, the term "oxidation-sensitive
hydrophilic active principle" is understood to mean any active
principle of natural or synthetic origin capable of undergoing
decomposition by an oxidation mechanism. This oxidation phenomenon
can have several causes, in particular the presence of oxygen, of
light or of metal ions, a high temperature or certain pH
conditions.
[0024] Mention may be made, by way of example and without implied
limitation, of: ascorbic acid and its derivatives, such as salts
and esters thereof, particularly the 5,6-di-O-dimethylsilyascorbate
(sold by Exsymol under the reference PRO-AA), the potassium salt of
dl-.alpha.-tocopheryl dl-ascorbyl phosphate (sold by Senju
Pharmaceutical under the reference SEPIVITAL EPC), magnesium
ascorbyl phosphate or sodium ascorbyl phosphate (sold by Roche
under the reference Stay-C 50). The principle is preferably present
in an amount sufficient to prevent and/or treat cutaneous signs of
ageing, such as 0.1, 1, 5 and 25 g per 100 g. Any principle useful
for this purpose and meeting the requirements of hydrophilicity and
oxidation sensitivity may be used.
[0025] In a particularly advantageous aspect, the
oxidation-sensitive hydrophilic active principle is ascorbic
acid.
[0026] According to the invention, the term "non-crosslinked
N-vinylimidazole polymer or copolymer" is understood to mean any
polymer comprising N-vinylimidazole units and not comprising a
crosslinking agent. Copolymers suitable for the implementation of
the invention are copolymers combining N-vinylimidazole with
N-vinylpyrrolidone and/or N-vinylcaprolactam subunits.
[0027] In an advantageous aspect of the invention, the copolymer
has a molar fraction of N-vinylimidazole units of between 0.1 and
1, more preferably between 0.4 and 0.9, inclusive.
[0028] According to an advantageous aspect of the invention, the
molar ratio of the N-vinylimidazole unit equivalent to the
oxidation-sensitive hydrophilic active principle varies between
0.004 and 16 and preferably between 0.01 and 1, inclusive.
[0029] Use will preferably be made of an
N-vinylimidazole/N-vinylpyrrolido- ne copolymer.
[0030] The weight-average molar mass of the N-vinylimidazole
polymers will advantageously be between 1 000 and 1.times.107 and
preferably between 5 000 and 5.times.106.
[0031] Use may be made, to this end, of the
vinylpyrrolidone/vinylimidazol- e (50/50) copolymer having a
weight-average molar mass of 1 200 000 sold under the reference
LUVITEC VPI 55K72W by BASF or the vinylpyrrolidone/vinylimidazole
(50/50) copolymer having a weight-average molar mass of 10 000 sold
under the reference LUVITEC VPI 55K18P by BASF.
[0032] The at least one polymer or copolymer is preferably present
in the composition according to the invention in an amount
sufficient to produce the desired effect, that is to say in an
amount sufficient to stabilize the oxidation-sensitive hydrophilic
active principle. Preferably, the copolymer is present at a
concentration of between 0.1 and 5% by weight with respect to the
total weight of the aqueous phase and more particularly at a
concentration of between 0.1 and 2% by weight with respect to the
total weight of the aqueous phase, inclusive. Preferably the amount
stabilizes the active principle by slowing or stopping
decomposition at 45.degree. C. for two months.
[0033] The compositions used according to the invention are
preferably intended for topical application to the skin and/or its
superficial body growths and therefore comprise a physiologically
acceptable medium, that is to say a medium compatible with
cutaneous tissues, such as the skin, scalp, eyelashes, eyebrows,
hair, nails and mucous membranes. This physiologically acceptable
medium comprises an aqueous phase and optionally a physiologically
acceptable organic solvent chosen, for example, from lower alcohols
comprising from 1 to 8 carbon atoms and in particular from 1 to 6
carbon atoms, such as ethanol, isopropanol, propanol or butanol;
polyethylene glycols having from 6 to 80 ethylene oxide units; or
polyols, such as propylene glycol, isoprene glycol, butylene
glycol, glycerol or sorbitol.
[0034] When the physiologically acceptable medium is an aqueous
medium, it generally preferably has a pH which is compatible with
the skin, preferably ranging from 3 to 9 and better still from 3.5
to 7.5.
[0035] The compositions according to the invention can be provided
in any form, including any pharmaceutical dosage form used for
topical application and in particular in the form of aqueous or
aqueous/alcoholic solutions, of oil-in-water (O/W) or water-in-oil
(W/O) or multiple (triple: W/O/W or O/W/O) emulsions, of aqueous
gels or of dispersions of a fatty phase in an aqueous phase using
spherules, it being possible for these spherules to be polymeric
nanoparticles, such as nanospheres and nanocapsules, or lipid
vesicles of ionic and/or nonionic type (liposomes, niosomes or
oleosomes). These compositions are prepared according to the usual
methods.
[0036] In addition, the compositions used according to the
invention can be more or less fluid and can have the appearance of
a white or coloured cream, of an ointment, of a milk, of a lotion,
of a serum, of a paste or of a foam. They can optionally be applied
to the skin in the form of an aerosol. They can also be provided in
a solid form, for example in the form of a stick.
[0037] When the composition used according to the invention
comprises an oily phase, the latter preferably comprises at least
one oil. It can additionally comprise other fatty substances.
[0038] Mention may be made, as oils which can be used in the
composition of the invention, of, for example:
[0039] hydrocarbonaceous oils of animal origin, such as
perhydrosqualene;
[0040] hydrocarbonaceous oils of vegetable origin, such as liquid
triglycerides of fatty acids comprising from 4 to 10 carbon atoms,
such as triglycerides of heptanoic acid or octanoic acid, or
alternatively, for example, sunflower, maize, soybean, gourd, grape
seed, sesame, hazelnut, apricot, macadamia, arara, castor or
avocado oils, triglycerides of caprylic/capric acids, such as those
sold by Starineries Dubois or those sold under the names Miglyol
810, 812 and 818 by Dynamit Nobel, jojoba oil, or karite butter
oil;
[0041] synthetic esters and ethers, in particular of fatty acids,
such as the oils of formulae R1COOR2 and R1OR2 in which R1
represents the residue of a fatty acid comprising from 8 to 29
carbon atoms and R2 represents a branched or unbranched
hydrocarbonaceous chain comprising from 3 to 30 carbon atoms, such
as, for example, purcellin oil, isononyl isononanoate, isopropyl
myristate, 2-ethylhexyl palmitate, 2-octyldodecyl stearate,
2-octyldodecyl erucate or isostearyl isostearate; hydroxylated
esters, such as isostearyl lactate, octyl hydroxystearate,
octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl
citrate or heptanoates, octanoates or decanoates of fatty alcohols;
polyol esters, such as propylene glycol dioctanoate, neopentyl
glycol diheptanoate and diethylene glycol diisononanoate; and
pentaerythritol esters, such as pentaerythrityl
tetraisostearate;
[0042] linear or branched hydrocarbons of mineral or synthetic
origin, such as volatile or nonvolatile liquid paraffins and their
derivatives, liquid petrolatum, polydecenes or hydrogenated
polyisobutene, such as parleam oil;
[0043] fatty alcohols having from 8 to 26 carbon atoms, such as
cetyl alcohol, stearyl alcohol and their mixture (cetearyl
alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol,
2-undecylpentadecanol, oleyl alcohol or linoleyl alcohol;
[0044] partially hydrocarbon-comprising and/or silicone-comprising
fluorinated oils, such as those disclosed in the document
JP-A-2-295912;
[0045] silicone oils, such as volatile or nonvolatile
polymethylsiloxanes (PDMS) comprising a linear or cyclic silicone
chain which are liquid or pasty at ambient temperature, in
particular cyclopolydimethylsiloxanes (cyclomethicones), such as
cyclohexasiloxane; polydimethylsiloxanes comprising pendent alkyl,
alkoxy or phenyl groups or alkyl, alkoxy or phenyl groups at the
end of the silicone chain, which groups have from 2 to 24 carbon
atoms; or phenylated silicones, such as phenyl trimethicones,
phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxane- s,
diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes,
(2-phenylethyl)trimethylsiloxysilicates and
polymethylphenylsiloxanes;
[0046] their mixtures.
[0047] The term "hydrocarbonaceous oil" is understood to mean, in
the list of the oils mentioned above, any oil predominantly
comprising carbon and hydrogen atoms and optionally ester, ether,
fluorinated, carboxylic acid and/or alcohol groups.
[0048] The other fatty substances which can be present in the oily
phase are, for example, fatty acids comprising from 8 to 30 carbon
atoms, such as stearic acid, lauric acid, palmitic acid and oleic
acid; waxes, such as lanolin, beeswax, camauba or candelilla wax,
paraffin or lignite waxes or microcrystalline waxes, ceresin or
ozokerite, or synthetic waxes, such as polyethylene waxes or
Fischer-Tropsch waxes; silicone resins, such as trifluoromethyl
C1-4 alkyl dimethicone and trifluoropropyl dimethicone; and
silicone elastomers, such as the products sold under the names
"KSG" by Shin-Etsu, under the names "Trefil", "BY29" or "EPSX" by
Dow Corning or under the names "Gransil" by Grant Industries.
[0049] These fatty substances can be chosen in a way varied by a
person skilled in the art in order to prepare a composition having
the desired properties, for example of consistency or of texture,
without undue hardship.
[0050] According to a specific embodiment of the invention, the
composition according to the invention is a water-in-oil (W/O) or
oil-in-water (O/W) emulsion. The proportion of the oily phase in
the emulsion can preferably range from 5 to 80% by weight and
preferably from 5 to 50% by weight with respect to the total weight
of the composition.
[0051] The emulsions generally comprise at least one emulsifier
selected from the group consisting of amphoteric, anionic, cationic
or nonionic emulsifiers, used alone or as a mixture, and optionally
a coemulsifier. The emulsifiers are appropriately chosen according
to the emulsion to be obtained (W/O or O/W). The emulsifier and the
coemulsifier are generally present in the composition in a
proportion ranging from 0.3 to 30% by weight and preferably from
0.5 to 20% by weight with respect to the total weight of the
composition.
[0052] Mention may be made, for the W/O emulsions, for example, as
emulsifiers, of dimethicone copolyols, such as the mixture of
cyclomethicone and of dimethicone copolyol sold under the name "DC
5225 C" by Dow Coming, and alkyl dimethicone copolyols, such as the
laurylmethicone copolyol sold under the name "Dow Corning 5200
Formulation Aid" by Dow Coming and the cetyl dimethicone copolyol
sold under the name Abil EM 90R by Goldschmidt. Use may also be
made, as surfactant of W/O emulsions, of a crosslinked solid
organopolysiloxane elastomer comprising at least one oxyalkylenated
group, such as those obtained according to the procedure of
Examples 3, 4 and 8 of the document U.S. Pat. No. 5,412,004 and the
examples of the document U.S. Pat. No. 5,811,487, in particular the
product of Example 3 (synthetic example) of patent U.S. Pat. No.
5,412,004, and such as that sold under the reference KSG 21 by Shin
Etsu. Use may also be made, as emulsifier, of a polyolefin-derived
oligomer or polymer comprising a succinic ending; the latter is
preferably a polyolefin comprising an esterified or amidated
succinic ending or a salt of such a polyolefin and in particular
polyisobutylene comprising an esterified or amidated succinic
ending such as the products sold under the names L5603 and L2721
and OS131769 by Lubrizol.
[0053] Mention may be made, for the O/W emulsions, for example, as
emulsifiers, of nonionic emulsifiers, such as esters of fatty acids
and of glycerol which are oxyalkylenated (more particularly
polyoxyethylenated); esters of fatty acids and of sorbitan which
are oxyalkylenated; esters of fatty acids which are oxyalkylenated
(oxyethylenated and/or oxypropylenated); ethers of fatty alcohols
which are oxyethylenated (oxyethylenated and/or oxypropylenated);
sugar esters, such as sucrose stearate; and their mixtures, such as
the mixture of glyceryl stearate and of PEG-40 stearate.
[0054] The composition of the invention can also comprise adjuvants
known in the cosmetics or dermatological field, such as hydrophilic
or lipophilic gelling agents, preservatives, solvents, fragrances,
fillers, UV screening agents, bactericides, odour absorbers,
colouring materials, plant extracts or salts. The amounts of these
various adjuvants are those conventionally used in the field under
consideration, for example from 0.01 to 20% of the total weight of
the composition. These adjuvants, depending on their nature, can be
introduced into the fatty phase, into the aqueous phase and/or into
the lipid spherules.
[0055] Mention may be made, as fillers which can be used in the
composition of the invention, for example, of pigments, silica
powder; talc; particles of polyamide and in particular those sold
under the name Orgasol by Atochem; polyethylene powders;
microspheres based on acrylic copolymers, such as those made of
ethylene glycol dimethacrylate/lauryl methacrylate copolymer which
are sold by Dow Corning under the name Polytrap; expanded powders,
such as hollow microspheres and in particular the microspheres sold
under the name Expancel by Kemanord Plast or under the name
Micropearl F 80 ED by Matsumoto; silicone resin microbeads, such as
those sold under the name Tospearl by Toshiba Silicone; and their
mixtures. These fillers can be present in amounts ranging from 0 to
20% by weight and preferably from 1 to 10% by weight with respect
to the total weight of the composition.
[0056] According to a preferred embodiment, the compositions in
accordance with the invention can additionally comprise at least
one organic photoprotective agent and/or at least one inorganic
photoprotective agent which is active in the UV-A and/or UV-B
regions (absorbers), and which are soluble in water or in fats or
else are insoluble in the cosmetic solvents commonly used.
[0057] The organic photoprotective agents are chosen in particular
from anthranilates; cinnamic derivatives; dibenzoylmethane
derivatives; salicylic derivatives; camphor derivatives; triazine
derivatives, such as those disclosed in patent applications U.S.
Pat. No. 4,367,390, EP 863 145, EP 517 104, EP 570 838, EP 796 851,
EP 775 698, EP 878 469, EP 933 376, EP 507 691, EP 507 692, EP 790
243 and EP 944 624; benzophenone derivatives;
.beta.,.beta.-diphenylacrylate derivatives; benzotriazole
derivatives; benzalmalonate derivatives; benzimidazole derivatives;
imidazolines; bisbenzoazolyl derivatives as disclosed in Patents EP
669 323 and U.S. Pat. No. 2,463,264; p-aminobenzoic acid (PABA)
derivatives; methylenebis(hydroxyphenylbenzotriazole) derivatives
as disclosed in applications U.S. Pat. No. 5,237,071, U.S. Pat. No.
5,166,355, GB 2 303 549, DE 197 26 184 and EP 893 119; screening
polymers and screening silicones, such as those disclosed in
particular in Application WO 93/04665; dimers derived from
.alpha.-alkylstyrene, such as those disclosed in Patent Application
DE 198 55 649; 4,4-diarylbutadienes as disclosed in Applications EP
0 967 200, DE 197 46 654, DE 197 55 649, EP-A-1 008 586, EP 1 133
980 and EP 133 981; and their mixtures.
[0058] By way of illustration, mention may be made, as
photoprotective agents which are active in the UV-A and/or UV-B
regions, denoted below under their INCI names, of:
[0059] p-aminobenzoic acid (PABA) derivatives, in particular PABA,
ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA
(sold in particular under the name "Escalol 507" by ISP), glyceryl
PABA or PEG-25 PABA (sold under the name "Uvinul P25" by BASF),
[0060] salicylic derivatives, in particular homosalate (sold under
the name "Eusolex HMS" by Rona/EM Industries), ethylhexyl
salicylate (sold under the name "Neo Heliopan OS" by Haarmann and
Reimer), dipropylene glycol salicylate (sold under the name
"Dipsal" by Scher), or TEA salicylate (sold under the name "Neo
Heliopan TS" by Haarmann and Reimer),
[0061] dibenzoylmethane derivatives, in particular butyl
methoxydibenzoylmethane (sold in particular under the trade name
"Parsol 1789" by Hoffmann-LaRoche), or isopropyl
dibenzoylmethane,
[0062] cinnamic derivatives, in particular ethylhexyl
methoxycinnamate (sold in particular under the trade name "Parsol
MCX" by Hoffmann-LaRoche), isopropyl methoxycinnamate, isoamyl
methoxycinnamate (sold under the trade name "Neo Heliopan E 1000"
by Haarmann and Reimer), cinoxate, DEA methoxycinnamate,
diisopropyl methyl cinnamate, or glyceryl ethylhexanoate
dimethoxycinnamate,
[0063] .beta.,.beta.-diphenylacrylate derivatives, in particular
octocrylene (sold in particular under the trade name "Uvinul N539"
by BASF) or etocrylene (sold in particular under the trade name
"Uvinul N35" by BASF),
[0064] benzophenone, in particular benzophenone-1 (sold under the
trade name "Uvinul 400" by BASF), benzophenone-2 (sold under the
trade name "Uvinul D50" by BASF), benzophenone-3 or oxybenzone
(sold under the trade name "Uvinul M40" by BASF), benzophenone-4
(sold under the trade name "Uvinul MS40" by BASF), benzophenone-5,
benzophenone-6 (sold under the trade name "Helisorb 11" by
Norquay), benzophenone-8 (sold under the trade name "Spectra-Sorb
UV-24" by American Cyanamid), benzophenone-9 (sold under the trade
name "Uvinul DS-49" by BASF), benzophenone-12, or n-hexyl
2-(4-diethylamino-2-hydroxybenzoyl)benzoate,
[0065] benzylidene camphor derivatives, in particular 3-benzylidene
camphor (manufactured under the name "Mexoryl SD" by Chimex),
4-methylbenzylidene camphor (sold under the name "Eusolex 6300" by
Merck), benzylidene camphor sulphonic acid (manufactured under the
name "Mexoryl SL" by Chimex), camphor benzalkonium methosulphate
(manufactured under the name "Mexoryl SO" by Chimex),
terephthalylidene dicamphor sulphonic acid (manufactured under the
name "Mexoryl SX" by Chimex), or polyacrylamidomethyl benzylidene
camphor (manufactured under the name "Mesoryl SW" by Chimex),
[0066] benzimidazole derivatives, in particular phenylbenzimidazole
sulphonic acid (sold in particular under the trade name "Eusolex
232" by Merck), or disodium phenyl dibenzimidazole tetrasulphonate
(sold under the trade name "Neo Heliopan AP" by Haarmann and
Reimer),
[0067] triazine derivatives, in particular anisotriazine (sold
under the trade name "Tinosorb S" by Ciba Specialty Chemicals),
ethylhexyl triazone (sold in particular under the trade name
"Uvinul T150" by BASF), diethylhexyl butamido triazone (sold under
the trade name "Uvasorb HEB" by Sigma 3V) or 2,4,6-tris(diisobutyl
4'-amino-benzalmalonate)-s-triazine- ,
[0068] benzotriazole derivatives, in particular drometrizole
trisiloxane (sold under the name "Silatrizole" by Rhodia Chimie) or
methylene bisbenzotriazolyl tetramethylbutylphenol (sold in the
solid form under the trade name "Mixxim BB/100" by Fairmount
Chemical or in the micronized form in aqueous dispersion under the
trade name "Tinosorb M" by Ciba Specialty Chemicals),
[0069] anthranilic derivatives, in particular menthyl anthranilate
(sold under the trade name "Neo Heliopan MA" by Haarmann and
Reimer),
[0070] imidazoline derivatives, in particular ethylhexyl
dimethoxybenzylidene dioxoimidazoline propionate,
[0071] benzalmalonate derivatives, in particular polyorganosiloxane
comprising benzalmalonate functional groups (sold under the trade
name "Parsol SLX" by Hoffmann-LaRoche),
[0072] 4,4-diarylbutadiene derivatives, in particular
1,1'-dicarboxy (2,2'-dimethyl-propyl)-4,4-diphenylbutadiene,
[0073] and their mixtures.
[0074] The organic photoprotective agents which are more
particularly preferred are selected from the group consisting of
ethylhexyl salicylate, ethylhexyl methoxycinnamate, octocrylene,
phenylbenzimidazole sulphonic acid, benzophenone-3, benzophenone-4,
benzophenone-5, 4-methylbenzylidene camphor, terephthalylidene
dicamphor sulphonic acid, disodium phenyl dibenzimidazole
tetrasulphonate, 2,4,6-tris(diisobutyl
4'-aminobenzalmalonate)-s-triazine, anisotriazine, ethylhexyl
triazone, diethylhexyl butamido triazone, methylene
bisbenzotriazolyl tetramethylbutylphenol, drometrizole trisiloxane,
1,1'-dicarboxy (2,2'-dimethylpropyl)-4,4-diphenylbutadiene, and
their mixtures.
[0075] The inorganic photoprotective agents may be selected from
the group consisting of pigments or alternatively nanopigments
(mean size of the primary particles: generally between 5 nm and 100
nm, preferably between 10 nm and 50 nm) formed from coated or
uncoated metal oxides, such as, for example, titanium oxide
(amorphous or crystalline in the rutile and/or anatase form), iron
oxide, zinc oxide, zirconium oxide or cerium oxide nanopigments,
which are all UV photoprotective agents well known per se.
Conventional coating agents are, furthermore, alumina and/or
aluminium stearate. Such nanopigments formed from coated or
uncoated metal oxides are disclosed in particular in Patent
Applications EP 518 772 and EP 518 773.
[0076] The photoprotective agents are generally preferably present
in the compositions according to the invention in proportions
ranging from 0.1 to 20% by weight with respect to the total weight
of the composition and preferably ranging from 0.2 to 15% by weight
with respect to the total weight of the composition.
[0077] In another advantageous aspect of the invention, the
composition can additionally (that is, in addition to the principle
described above) comprise at least one other active principle which
stimulates dermal macromolecules or which prevents their
decomposition and/or one agent which stimulates the proliferation
of fibroblasts or keratinocytes and/or the differentiation of
keratinocytes.
[0078] Examples include active principles which stimulate dermal
macromolecules or which prevent their decomposition, those which
act:
[0079] either on the synthesis of collagen, such as extracts of
Centella asiatica; asiaticosides and derivatives; ascorbic acid or
vitamin C and its derivatives, synthetic peptides, such as iamine,
biopeptide CL or the palmitoyloligopeptide sold by Sederma;
peptides extracted from plants, such as the soybean hydrolysate
sold by Coletica under the trade name Phytokine.RTM.; and plant
hormones, such as auxins;
[0080] or on the synthesis of elastin, such as the extract of
Saccharomyces cerevisiae sold by LSN under the trade name
Cytovitin.RTM.; and the extract of the alga Macrocystis pyrifera
sold by Secma under the trade name Kelpadelie.RTM.;
[0081] or on the synthesis of glycosaminoglycans, such as the
product of fermentation of milk by Lactobacillus vulgaris sold by
Brooks under the trade name Biomin yogourth.RTM.; the extract of
the brown alga Padina pavonica sold by Alban Muller under the trade
name HSP3.RTM.; and the extract of Saccharomyces cerevisiae
available in particular from Silab under the trade name
Firmalift.RTM. or from LSN under the trade name Cytovitin.RTM.;
[0082] or on the synthesis of fibronectin, such as the extract of
Salina zooplankton sold by Seporga under the trade name
GP4G.RTM.;
[0083] the yeast extract available in particular from Alban Muller
under the trade name Drieline.RTM.; and the palmitoyl pentapeptide
sold by Sederma under the trade name Matrixil.RTM.;
[0084] or on the inhibition of metalloproteinases (MMP), such as
more particularly MMP 1, 2, 3 or 9. Mention may be made of:
retinoids and derivatives; oligopeptides and lipopeptides,
lipoamino acids; the malt extract sold by Coletica under the trade
name Collalift.RTM.; extracts of blueberry or of rosemary;
lycopene; or isoflavones, their derivatives or the plant extracts
comprising them, in particular extracts of soybean (sold, for
example, by Ichimaru Pharcos under the trade name Flavosterone
SB.RTM.), of red clover, of flax, of kakkon or of sage;
[0085] or on the inhibition of serine proteases, such as leukocyte
elastase or cathepsin G. Mention may be made of: the peptide
extract of Leguminosae (Pisum sativum) seeds sold by LSN under the
trade name Parelastyl.RTM.; heparinoids; and pseudodipeptides.
[0086] Mention may in particular be made, among the active
principles which stimulate epidermal macromolecules, such as
filaggrin and keratins, of the extract of lupin sold by Silab under
the trade name Structurine.RTM.; the extract of beech Fagus
sylvatica buds sold by Gattefoss under the trade name
Gatuline.RTM.; and the extract of Salina zooplankton sold by
Seporga under the trade name GP4G.RTM..
[0087] The agents which stimulate the proliferation of fibroblasts
which can be used in the composition according to the invention
can, for example, be selected from the group consisting of plant
proteins or polypeptides, extracts, in particular of soybean (for
example, a soybean extract sold by LSN under the name Eleseryl
SH-VEG 8.RTM. or sold by Silab under the trade name
Raffermine.RTM.); and plant hormones, such as gibberellins and
cytokinins.
[0088] The agents which stimulate the proliferation of
keratinocytes which can be used in the composition according to the
invention may comprise in particular retinoids, such as retinol and
its esters, including retinyl palmitate; phloroglucinol ; the
extracts of walnut meal sold by Gattefoss; and the extracts of
Solanum tuberosum sold by Sederma.
[0089] The agents which stimulate the differentiation of
keratinocytes include for example inorganic materials, such as
calcium; the extract of lupin sold by Silab under the trade name
Photoprventine.RTM.; sodium .beta.-sitosteryl sulphate, sold by
Seporga under the trade name Phytocohsine.RTM.; and the extract of
maize sold by Solabia under the trade name Phytovityl.RTM..
[0090] The composition according to the invention can be applied to
the skin or mucous membranes. It can thus be used in a cosmetic
treatment process for the purpose of preventing and/or treating
cutaneous signs of intrinsic ageing, comprising the application of
the composition according to the invention to the skin or mucous
membranes, particularly skin or membranes especially subject to
such ageing and its signs, and more particularly such skin and
membranes visible in normal activity.
[0091] In an alternative form, the composition according to the
invention can be used for the manufacture of a dermatological
preparation comprising an aqueous phase which is intended to
prevent and/or treat cutaneous signs of intrinsic ageing.
[0092] The examples which follow serve to illustrate the invention
without, however, exhibiting a limiting nature. The compounds are,
depending on the situation, cited according to chemical names or
according to CTFA (International Cosmetic Ingredient Dictionary and
Handbook) names.
EXAMPLES
Example 1
[0093] Accelerated Storage Test.
[0094] The aim of this test is to study the decomposition of an
oxidation-sensitive hydrophilic active principle after storing for
two months at 45.degree. C. Various solutions were prepared and
their compositions are collated in the following table:
1TABLE I Compositions (in Solution A water) Control Solution B
Solution C Solution D Ascorbic acid 15% 15% 15% 15% Polymer 1 -- 1%
-- -- Polymer 2 -- -- 1% -- Polymer 3 -- -- -- 1%
[0095] All the solutions are brought to pH 6 with 8.9 mol/l
KOH.
[0096] The percentages of the polymers are given as active
material.
[0097] Polymer 1: Vinylpyrrolidone/vinylimidazole (50/50) copolymer
sold under the reference Luvitec VPI 55K72W of BASF (Weight-average
molecular mass 1.2.times.10.sup.6).
[0098] Polymer 2: Vinylpyrrolidone/vinylimidazole (50/50) copolymer
sold under the reference Luvitec VPI 55K8P of BASF (Weight-average
molecular mass 10 000).
[0099] Polymer 3: Polyvinylpyrrolidone sold under the reference
Kollidon 12PF of BASF (Weight-average molecular mass 3 000).
[0100] The degree of decomposition measured is given by the
ratio:
(C0-C2 months)/C0
[0101] with C0 concentration of ascorbic acid at t=0 and C2 months
the concentration of ascorbic acid at t=2 months, under the
conditions indicated in the above table.
[0102] The concentration of ascorbic acid is determined by the HPLC
technique (LaChrom Merck system). The analytical conditions are as
follows:
[0103] Column: Lichrosphere100 RP18 (250 mm)
[0104] Eluent: 0.1M phosphate buffer, pH 2.1
[0105] Flow rate: 1 ml/min
[0106] Detection at 257 nm
[0107] Dilution of the sample such that the concentration of
ascorbic acid is between 0.05 and 1 mg/ml.
[0108] The results obtained are collated in the following Table
II:
2 TABLE II Degree of decomposition after 2 months at 45.degree. C.
(in %) under air, amber glass bottle under nitrogen, aluminium
flask Solution A 43 19.4 Solution B 10.8 1 Solution C 23.4 4.5
Solution D 35.8 15.7
[0109] It is found, from Table II, that the stability of ascorbic
acid is improved in the presence of Polymer 1 and Polymer 2 of the
invention, even in the presence of atmospheric oxygen, in
comparison with the control. It is also found that the
N-vinylpyrrolidone homopolymer alone is not sufficient to
effectively stabilize the ascorbic acid solution.
[0110] As the polymers mentioned are hydrophilic, it will be
sufficient to add them to an aqueous ascorbic acid solution to
stabilize the ascorbic acid.
Example 2
[0111] Observation of the Effect of the Addition of a Combination
According to the Invention on the Synthesis of Tenascin and of
Collagen VII:
[0112] The present example describes the effects of the addition of
a combination according to the invention, comprising ascorbic acid
and a polymer or copolymer according to the invention, on
reconstructed skin by observation with a microscope of a skin
section with immunohistochimical labelling of the proteins of
tenascin and collagen VII.
[0113] 1. Preparation of the Reconstructed Skin
[0114] The reconstructed skin used is prepared according to the
protocol described in Asselineau et al. (Models in Dermato.
Published by Loire and Maibach, 1987, Vol III, 1-7). The
modifications to this protocol are:
[0115] the use of normal adult human dermal fibroblasts in a
proportion of 106 cells per equivalent dermis;
[0116] the inoculation of the keratinocytes is carried out in a
proportion of 50 000 cells per ring with a diameter of 1.5 cm. The
keratinocytes used originate from the same donor and are at passage
1 during the inoculation of the dermal equivalents;
[0117] the duration of the immersion phase is 7 days;
[0118] the duration of the emergence phase is 7 days.
[0119] 2. Addition of the Combination According to the
Invention:
[0120] The final change in medium of the immersion phase is carried
out in the presence of the combination of ascorbic acid and of
vinylpyrrolidone/vinylimidazole. The culture is subsequently
mounted on a grid for the emergence phase (7 days) and, during this
phase, all changes in medium (every 2 days) are carried out in the
presence of the above combination.
[0121] 3.a. Analysis of Collagen VII
[0122] The reconstructed skins are analysed at the end of the
emergence phase. A control sample is systematically prepared and
analysed in parallel.
[0123] The samples are taken and frozen in liquid nitrogen. The
blocks are produced from Tissue Teck. Collagen of type VII is
detected by immunohistochemistry on frozen sections with a
thickness of 5 .mu.m. The conventional indirect immunofluorescence
technique is carried out with an anticollagen VII monoclonal
antibody (LH7.2, Chemicon International Inc., USA) and a
fluorescein-coupled conjugate (FITC-conjugated Rabbit anti mouse
immunoglobulins, DAKO, Denmark).
[0124] 3.b. Analysis of Tenascin
[0125] The protocol used is that described in point 3.a. above,
except that, in this case, the tenascin is detected with an
antitenascin monoclonal antibody (TN2, Chemicon) and a
fluorescein-coupled conjugate (FITC-conjugated Rabbit anti mouse
immunoglobulins, DAKO, Denmark).
[0126] 4. Observations:
[0127] On observing with a microscope, it is found that the
intensity and the thickness of the fluorescence region
corresponding to the dermoepidermal junction is much greater in the
sample to which the ascorbic acid and
vinylpyrrolidone/vinylimidazole copolymer combination has been
added. This was observed both for the analysis of collagen VII and
for the analysis of tenascin.
Example 3
[0128] O/W Anti-Ageing Cream
[0129] The following composition is prepared in a way conventional
to a person skilled in the art.
3 Water 16 g Glycerol 3 g Sorbitan tristearate 0.68 g PEG-40
stearate 1.5 g Cetyl alcohol 3 g Glyceryl stearate 2.25 g Myristyl
myristate 1.5 g Ethylhexyl palmitate 1.5 g Hydrogenated
polyisobutene 2.5 g Shorea robusta seed butter 1.5 g Butyrospermum
parkii (shea butter) fruit 0.5 g Cyclopentasiloxane 7.5 g
Phenoxyethanol 1 g Water 46.24 g Ascorbic acid 5 g Potassium
hydroxide (50% solution) 3 g Vinylpyrrolidone/vinylimi- dazole
copolymer 1 g
[0130] This rich and soft cream makes it possible to combat signs
of intrinsic ageing and has good stability for the ascorbic
acid.
Example 4
[0131] Anti-Ageing Cream
[0132] The following composition is prepared in a way conventional
to a person skilled in the art.
4 Pentaerythrityl tetraethylhexanoate 6 g Ammonium
polyacryloyldimethyl taurate 0.6 g Water 14.95 g Methylparaben 0.2
g Glycerol 3 g Phenoxyethanol 0.5 g PTFE 4 g Cetearyl alcohol (and)
ceteareth-30 1.5 g Octocrylene 7 g Butyl methoxydibenzoylmethane 2
g Ethylhexyl salicylate 5 g Glycolipids 0.5 g Propylparaben 0.1 g
Petrolatum 1 g Polysorbate 60 1 g Cetyl alcohol 0.5 g Caprylyl
glycol 0.15 g Glyceryl starch 2 g Water 41 g Ascorbic acid 5 g
Potassium hydroxide (50% solution) 3 g
Vinylpyrrolidone/vinylimidazole copolymer 1 g
[0133] This cream which is soft and fresh on application makes it
possible to combat wrinkles and fine lines and has a good degree of
stabilization for the ascorbic acid.
[0134] The above description of the invention, as illustrated by
non-limiting examples, allows one of ordinary skill in this art to
make and use, for preventing and/or treating cutaneous signs of
intrinsic ageing, a composition comprising, preferably in a
physiologically acceptable medium comprising an aqueous phase, at
least one oxidation-sensitive hydrophilic active principle for
example selected from the group consisting of ascorbic acid and its
derivatives and at least one non-crosslinked N-vinylimidazole
polymer or copolymer, the active principle and the polymer or
copolymer both being present in the aqueous phase. Also provided is
the use of a combination comprising at least one
oxidation-sensitive hydrophilic active principle selected from the
group consisting of ascorbic acid and its derivatives and of at
least one non-crosslinked N-vinylimidazole polymer or copolymer in
the aqueous phase of a cosmetic composition as an agent for
preventing and/or treating cutaneous signs of intrinsic ageing.
Also provided is the use of at least one oxidation-sensitive
hydrophilic active principle selected from the group consisting of
ascorbic acid and its derivatives and of at least one
non-crosslinked N-vinylimidazole polymer or copolymer for the
preparation of a dermatological composition comprising an aqueous
phase which is intended to prevent and/or treat cutaneous signs of
intrinsic ageing. Also provided is a cosmetic treatment process
intended to prevent and/or treat cutaneous signs of intrinsic
ageing, comprising the application, to the skin or mucous
membranes, of a composition comprising, preferably in a
physiologically acceptable medium comprising an aqueous phase, at
least one oxidation-sensitive hydrophilic active principle selected
from the group consisting of ascorbic acid and its derivatives and
at least one non-crosslinked N-vinylimidazole polymer or copolymer,
the active principle and the polymer or copolymer both being in the
aqueous phase. Also provided is a method for preventing and/or
treating cutaneous signs of intrinsic ageing, comprising applying a
composition comprising a physiologically acceptable medium
comprising an aqueous phase, at least one oxidation-sensitive
hydrophilic active principle selected from the group consisting of
ascorbic acid and its derivatives, and at least one non-crosslinked
N-vinylimidazole polymer or copolymer to a cutaneous tissue, the
active principle and the polymer or copolymer both being present in
the aqueous phase of the composition.
[0135] French patent application 0115375 is incorporated herein by
reference, as are all references, texts, documents, patents,
applications, standards, etc. mentioned above. Where a numerical
range is stated all values therebetween are included as if
specifically written out.
[0136] Also incorporated herein by reference are the following U.S.
applications, all filed Nov. 27, 2002, where the present
application is listed for information only:
[0137] U.S. Serial No. . . . (Atty. Docket 230634US0)
[0138] U.S. Serial No. . . . (Atty. Docket 230608US0)
[0139] U.S. Serial No. . . . (Atty. Docket 230616US0)
[0140] U.S. Serial No. . . . (Atty. Docket 230614US0)
[0141] U.S. Serial No. . . . (Atty. Docket 230615US0)
* * * * *